Glimepiride Accord

Glimepiride Accord is a prescription oral medication containing the active ingredient glimepiride, a second‑generation sulfonylurea, supplied in tablet form at the strength indicated on the label. It is marketed in the European Union and is used as an oral hypoglycemic agent for the management of type 2 diabetes mellitus. It stimulates insulin release from pancreatic beta cells and is used with diet, exercise, and glucose monitoring.

Glimepiride Accord is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and weight management alone do not achieve adequate glycemic control.

- As monotherapy in patients with newly diagnosed type 2 diabetes. - In combination with metformin when metformin alone is insufficient. - As adjunct to other oral antidiabetic agents such as thiazolidinediones. - For patients who require additional glucose lowering after lifestyle measures. - In combination with insulin for patients needing tighter control. - For patients with renal impairment where dose adjustment is appropriate.

The safety profile of Glimepiride Accord includes both frequent, mild reactions and less common, potentially serious events.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed. - Weight gain. - Nausea or abdominal discomfort. - Headache or dizziness. - Fatigue or weakness. - Visual disturbances. - Dry mouth.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Blood disorders like leukopenia or thrombocytopenia. - Liver enzyme elevations.

When prescribing Glimepiride Accord, clinicians should consider several precautionary factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function before initiating therapy. - Monitor blood glucose regularly to detect hypoglycemia. - Use caution in elderly patients due to increased sensitivity. - Adjust dose in patients with cardiovascular disease. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Review concomitant medications that may potentiate hypoglycemia.

Glimepiride Accord can interact with several drugs, affecting blood sugar levels or increasing adverse effects.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole, which can raise glimepiride concentrations. - MAO‑B inhibitors, which may enhance hypoglycemic risk. - Alcohol, especially in excess, which can potentiate hypoglycemia.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may affect glucose control. - Anticoagulants like warfarin, as glimepiride may alter INR. - Corticosteroids, which may increase blood glucose and require dose adjustment. - Antidepressants such as SSRIs, which may have variable effects on glucose metabolism.